Trial · NCT00380068
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD) | Ambrisentan | 20.5 | Standard Deviation 65.64 | meters | |
| Change From Baseline to Week 24 in Borg Dyspnea Index | Ambrisentan | -0.5 | Standard Deviation 2.18 | Units on a scale | |
| Change From Baseline to Week 48 in Borg Dyspnea Index | Ambrisentan | -0.6 | Standard Deviation 1.91 | Units on a scale | |
| Percent Change From Baseline to Week 24 in B-type Natriuretic Peptide (BNP) | Ambrisentan | -25.5 | 95% Confidence Interval -33.6 to -16.3 | Percent change in BNP | |
| Percent Change From Baseline to Week 48 in BNP | Ambrisentan | -29.2 | 95% Confidence Interval -39.8 to -16.6 | Percent change in BNP | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | -3 | 0 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | -2 | 0.9 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | -1 | 22.2 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | 0 | 70.1 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | 1 | 6.8 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | 2 | 0 | Percentage of participants | |
| Change From Baseline to Week 24 in WHO Functional Class | Ambrisentan | 3 | 0 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | -3 | 0 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | -2 | 1.7 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | -1 | 34.5 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | 0 | 57.1 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | 1 | 6.7 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | 2 | 0 | Percentage of participants | |
| Change From Baseline to Week 48 in WHO Functional Class | Ambrisentan | 3 | 0 | Percentage of participants | |
| Change From Baseline to Week 24 in SF-36 Health Survey Physical Functioning Scale | Ambrisentan | 2.88 | Standard Deviation 7.943 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00380068/results